x.com· @ · X·· 2026-04-23Score60
Body
Combining ramucirumab with pembrolizumab did not improve OS vs SOC for patients with previously treated stage IV or recurrent NSCLC.
⬇️ For more from the phase 2 SWOG S2302 PRAGMATICA-LUNG trial ⬇️
https://t.co/WSFV7v5NVj
#lcsm #NSCLC #AACR26 #oncology | @ReckampK
Heat 0 · 0 likes · 0 replies · 0 reposts
Conference abstracts
CT140matched by 药名 ramucirumab
Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Maya Khalil, Brian S. Henick, James Moon, Pasarlai Ahmadzai, Michael LeBlanc, Daniel R. Carrizosa, Paul J. Hesketh, Ellen V. Sigal, Jeff Allen, Andreas N. Saltos, Bryan A. Faller, Roy S. Herbst, Charles D. Blanke, Jhanelle E. Gray
Read the abstract →Source: x.com · x.com